• Save
Trudy Dehue - Selling Sickness 2010
Upcoming SlideShare
Loading in...5
×
 

Trudy Dehue - Selling Sickness 2010

on

  • 2,551 views

 

Statistics

Views

Total Views
2,551
Views on SlideShare
2,471
Embed Views
80

Actions

Likes
1
Downloads
0
Comments
1

3 Embeds 80

http://www.darkpharma.nl 56
http://www.weebly.com 23
http://www.linkedin.com 1

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
  • One of the most heralded marketing ploys ever to hit southeast Michigan (USA) area is a radio ad that is clearly intended to scare the listener into believing that undetected disease is lurking in their body. It strongly implies that the Sword of Damocles is hanging overhead and concludes in a deep, serious, probing voice, 'Do YOU have a Beaumont doctor?' Pervasive 'learned helplessness' with respect to caring for one's health apart from the 'salvation of modern medicine'. Persistent, intentional attacks to destroy one's confidence in even the most fundamental abilities of the body to restore homeostasis. And now the target is CHILDREN. Common sense health and hygiene practices have been supplanted by 'sickness management' from cradle to grave.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Trudy Dehue - Selling Sickness 2010 Trudy Dehue - Selling Sickness 2010 Presentation Transcript

  • Driven to service whose needs? On clinical trials as marketing instruments Trudy Dehue, professor of Theory and History of Science 1
  • RCT Randomised clinical trial Randomly composed Experimental Test group(s) Control Test group 2
  • Randomised clinical trial (RCT) Phase I: small group of subjects; safety check. Phase II: larger group of subjects; test for intended e and side-effects Phase III: repeat phase II with a larger group of subjects. Phase IV: post- (or peri-) marketing research; control for effects and safety in various populations a with long-term use. 3
  • Good, P. (2006) A manager’s guide to the design and conduct of clinical trials. 4
  • Contract Research Organisations (CROs) 5
  • 6
  • 7
  • Contract Research Organisations (CROs) 8
  • 9
  • When researchers are driven to service companies’ needs -trials become demonstrations -research becomes marketing -articles become advertisements -authors become authorities 10
  • When researchers are driven to service companies’ needs -trials become demonstrations -research becomes marketing -articles become advertisements -authors become authorities 11
  • 12
  • 13
  • 14
  • British Medical Journal, 2008, 377, p.603 British Medical journal, 15
  • Richard Smith Fiona Godlee (2008) (2005) ‘The evidence that ‘Medical journals industry funding are an extension of biases the design the marketing arm and reporting of of pharmaceutical clinical research is companies’ overwhelming’
  • “It is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgment of trusted physicians or authoritative medical guidelines” (Marcia Angell, former editor of The New England Journal of Medicine in The New York Review of Books, 2009).
  • BMJ, 8 December 2009 "The current system isn’t working. Worse than that, it gives 18 a false sense of security"
  • Food and Drug Administration College ter Beoordeling van Geneesmiddelen 19
  • 20
  • When researchers are driven to service companies’ needs -trials become demonstrations -research becomes marketing -articles become advertisements -authors become authorities 21
  • When researchers are driven to service companies’ needs -trials become demonstrations -research becomes marketing -articles become advertisements -authors become authorities 22
  • Minutes Dutch parlement, 2009 Law on medical scientific research 23
  • 24
  • www.quintiles.com
  • www.parexel.com 27
  • www.testim.com 28
  • 29
  • 30
  • In Phase IV your focus is on generating market uptake for your product (...). Covance can help launch your product (...). 31
  • 32
  • Umbach, 2007 33
  • 34
  • 35
  • Simon & Kotler (2003) 36
  • 37
  • 38
  • When researchers are driven to service companies’ needs -trials become demonstrations -research becomes marketing -articles become advertisements -authors become authorities 39
  • When researchers are driven to service companies’ needs -trials become demonstrations -research becomes marketing -articles become advertisements -authors become authorities 40
  • Uit Pharmaceutical Executive, 2008
  • 42
  • January 17 2008 Volume 358:252-260 Number 3 Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy Erick H. Turner, M.D., Annette M. Matthews, M.D., Eftihia Linardatos, B.S., Robert A. Tell, L.C.S.W., and Robert Rosenthal, Ph.D. 43
  • Article handed out by Janssen-Cilag at 2010 international psychiatry conference. Research sponsored by Janssen-Cilag. 44
  • When researchers are driven to service companies’ needs -trials become demonstrations -research becomes marketing -articles become advertisements -authors become authorities 45
  • When researchers are driven to service companies’ needs -trials become demonstrations -research becomes marketing -articles become advertisements -authors become authorities 46
  • Bleidt & Montagne (1997), p.251-252 ‘The direction provided by marketing is crucial to designing trials (...)’ 47
  • Bleidt & Montagne (1997), p.254 on ‘pre-approval marketing activities’: ‘This goal is accomplished through presentation of clinical information at scientific meetings, using posters and other exhibits, and the publication of articles in scientific journals’. 48
  • Social Studies of Science, 2004, 34, 187-218 On clinical trial researchers acting as mediators between producers and consumers 49
  • www.kendle.com 50
  • Berlin 51
  • PLoS Medicine, september 2009 and september 2010 52
  • PLoS Medicine, september 2010
  • BMJ, 4 april 2009, vol 388, p. 804-807 54 www.esf.org/fileadmin/links/EMRC/FL_IDCT.pdf
  • Recommendation CROs should be driven to service the needs of civilians rather than pharmaceutical companies. Hence, financially independent agencies should act as an interface between clinical trialists and pharmaceutical companies. 55
  • Driven to service whose needs? On clinical trials as the population’s instruments Trudy Dehue, professor of Theory and History of Science 56